CoreCap Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

CoreCap Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-41	Closed	-$516	–	3207
2025 Q1	$516	Sell	41 -43	-51%	-$517	﹤0.01%	2680
2024 Q4	$886	Buy	+84	New	+$1.18K	﹤0.01%	2398

Other funds holding SPRY

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CoreCap Advisors's SPRY Position: Q2 2025 in Review

CoreCap Advisors sold out of ARS Pharmaceuticals (SPRY) in Q2 2025, closing a stake of 41 shares — an estimated $516 sold.

CoreCap Advisors first reported a position in SPRY in Q4 2024 and held it in 2 quarters. The position peaked at $886 in Q4 2024. 187 funds tracked by Wall St. Rank hold SPRY as of Q2 2025.

CoreCap Advisors reported no remaining ARS Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 41 ARS Pharmaceuticals shares in Q2 2025, an estimated $516.
CoreCap Advisors first reported a position in ARS Pharmaceuticals in Q4 2024 and held it in 2 quarters.
CoreCap Advisors's ARS Pharmaceuticals position peaked at $886 in Q4 2024.
187 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.